Prostate cancer is the most common cancer diagnosed among the male population (Wong and Mohamad 2019). In May 2013, the FDA approved radium 223 Xofigo for clinical use to treat bone metastases from castration resistant prostate cancer (CRPC). The diagnosis of bone metastases within males initiates a poor prognosis, extreme pain and mortality. Radium 223 is an alpha particle that acts by delivering cytotoxic radiation to the sites of bone metastases. Since then, researchers have identified what radium 223 is and how it is so successful in extending the average survival of patients diagnosed with CRPC. Approving radium 223 for the market has shined a light on the entire world of radiopharmaceuticals and their ability to treat cancer. The research approach of this study examines the current protocols, dosing, and toxicity rates of radium 223 and allows for explanation of how the drug improves survival rates among patients with bone metastases from CRPC.

would like to thank their faculty sponsor Sherry Bicklein for their support for this project.